Clinical Trial

Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 3, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of Parts D and E of this Phase 1 study are to evaluate the safety, tolerability, and pharmacokinetics of multiple dose combinations of SION-451 and complementary modulators SION-2222 and SION-109 in healthy participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-16; most recent amendment 2025-09-02.
Status change: Not Yet Recruiting → Recruiting 2025-08-25
Trial Details
NCT Number NCT07035990
Lead Sponsor Sionna Therapeutics Inc.
Conditions Cystic Fibrosis (CF)
Enrollment 144 participants
Start Date 2025-07-23
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-03